Menu

Incomplete Immunity

By combining experimental data with computer models, researchers were able to predict a pathogen’s evolution toward more virulence.

Jun 1, 2018
Jim Daley

BYE BYE BIRDIE: A study suggests a weak immune response could drive pathogens toward greater virulence. MARIE READ

EDITOR’S CHOICE IN EVOLUTION

The paper
A.E. Fleming-Davies et al., “Incomplete host immunity favors the evolution of virulence in an emergent pathogen,” Science, 359:1030-33, 2018.

FINCH KILLER
Since 1994, an epidemic of conjunctivitis caused by the bacterium Mycoplasma gallisepticum has ravaged house finch (Haemorhous mexicanus) populations across North America. Arietta Fleming-Davies and Dana Hawley, disease ecologists at the University of San Diego and Virginia Tech, respectively, noted that many birds that had been infected remained susceptible to later infection. The phenomenon reminded Fleming-Davies of findings by other researchers that when a vaccine partially protects a host, it can drive a pathogen to evolve more virulence. (See “Do Pathogens Gain Virulence as Hosts Become More Resistant?The Scientist, October 2017.)

BIRD IN A CAGE
To find out whether something similar was happening in finches, the duo and their colleagues simulated the natural epidemic in the lab, infecting captive birds with increasingly virulent strains of M. gallisepticum and observing the severity of their symptoms. Fleming-Davis then used the data to model infection and the evolution of pathogen virulence in the wild.

CHINKS IN THE ARMOR
The model predicted almost twice as much virulence when bacterial attackers were confronted with incomplete immunity compared to zero immunity, Fleming-Davis tells The Scientist. This suggests, the authors write, that a weak immune response favors nastier pathogens that can overcome defenses.

NOT THE WHOLE STORY
That idea is “an interesting concept, especially as it relates to vaccine research,” says Molly Staley, an evolutionary biologist at the Brookfield Zoo, “but it doesn’t quite fit with what we know” about M. gallisepticum. The birds’ ability to resist manipulation of their immune systems by the bacteria is the primary driver of the pathogen’s increased virulence in the wild, Staley explains, adding that most of the birds infected in the wild are immunologically naïve juveniles, so the responses of previously infected birds likely have only a small effect on virulence evolution.

Correction (June 21): The photo credit on the image that accompanies this article originally referred to the wrong photographer and has been corrected. The Scientist regrets the error.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.